Le Lézard
Classified in: Health, Science and technology, Business
Subject: VEN

Zhiyi Biotech Raised $45 Million in Series B Funding Round to Accelerate the Clinical Development of LBPs Pipelines


GUANGZHOU, China, July 7, 2022 /PRNewswire/ -- Recently, Zhiyi Biotech announced that it has raised $15 million in its B++ funding round. The funds will be used to boost the clinical development of the company's live biotherapeutic products (LBPs) pipelines. It's worth mentioning that Zhiyi has successfully completed a total of $45 Million in B, B+ and B++ funding , with investors including Qingkong SinoKing Capital, SDIC Venture Capital, KIP etc.

Zhiyi is a clinical-stage biotech leading in LBPs in China. It has built up a complete technical and industrial platform, covering from the isolation and identification of new functional strains to the development of innovative LBPs. Notably, the lead drug candidate in Zhiyi's pipelines, SK08, is the first LBP developed on a unique bacterial strain Bacteroides Fragilis, and whose clinical progress is ahead of other LBPs in China. Phase II clinical trial of SK08 carried out in China to treat IBS-D is expected to be completed this year, and phase Ib/II trial of SK08 combined with PD-1 inhibitor for advance solid tumor has been initiated already. Meanwhile, several products are undergoing IND filing to both FDA and NMPA. More programs are expected to enter clinical stage in the foreseeing year.

"We are grateful to have the support and trust from our investors," said Dr. Ye Wang, CEO of Zhiyi Biotech. "The progress in our pipeline is attributed to our team's continuous effort and persistence in R&D. Zhiyi has been always focusing on the unmet medical needs and dedicating to develop accessible drugs to benefit more patients. We are looking forward to strengthening our international collaboration with peer companies, to promote development of the whole LBPs industry."

About Zhiyi Biotech

Zhiyi Biotech, founded in 2013, is located in Guangzhou, China. Its lead candidate SK08 is not only the first new strain-based LBP that entered clinical stage in China, but also the first LBP in oncology that was approved for clinical trial by NMPA. Owning two commercial-scale facilities, Zhiyi has established a complete platform system for strain selection, druggability study, CMC study, commercial production etc.

For more information, please visit https://www.zypharm.com.cn or contact public@zypharm.com.cn

SOURCE Zhiyi Biotech


These press releases may also interest you

at 19:48
Florida Polytechnic University unveiled its new Applied Research Center, a cutting-edge facility that will strengthen Florida Poly's position as a premier STEM institution and engine for economic development. The $47 million building expands the...

at 19:20
Groove, a leading sales productivity platform for enterprises using Salesforce®, today announced that it has been named to Inc. magazine's annual Inc. 5000 list of the fastest-growing privately held companies in the United States. Groove's three-year...

at 19:15
iHire has been named to the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. With revenue growth of 99.3% between 2018 to 2021, iHire earned a coveted spot on the list for the second straight...

at 19:05
Fortive Corporation ("Fortive") announced today that its Board of Directors declared a regular quarterly cash dividend of $0.07 per share of its common stock, par value $0.01 per share, payable on September 30, 2022 to common stockholders of record...

at 18:28
SS&C Technologies Holdings, Inc.  today announced its Board of Directors has approved a quarterly dividend payout of $0.20 per share, consistent with its quarterly dividend policy. The dividend is payable on September 15, 2022, to stockholders of...

at 18:10
Small businesses are at the heart of Canadian communities and are the engines that drive local economies. Their success is critical to accelerating inclusive growth that benefits everyone. The Honourable Mary Ng, Minister of International Trade,...



News published on 7 july 2022 at 05:45 and distributed by: